耐亚胺培南铜绿假单胞菌的药敏分析

Antimicrobial-resistant profile of imipenem-resistant Pseudomonas aeruginosa

目的：探讨我院2012~2013年临床分离出的耐亚胺培南铜绿假单胞菌的抗生素药敏情况,为临床合理使用抗菌药物提供指导。方法：采用VITEK2-Compact微生物鉴定仪及药敏分析系统对我院临床各标本进行鉴定及药敏分析,头孢哌酮/舒巴坦采用KB法。结果：2012~2013年分离到IRPA646株,对头孢菌素类耐药率为20.1%~100%,头孢他啶为43.3%,头孢吡肟为20.1%;对喹诺酮类抗生素耐药率为28.1%~30.4%;对氨基糖苷类耐药率为8.0%~12.9%;对β-内酰胺酶抑制剂类耐药率为24.5%~31.7%。结论：耐亚胺培南铜绿假单胞菌的耐药性严峻,临床应根据药敏结果选择用药,建议优先选用头孢他啶和头孢吡肟。

Objective ：To investigate the antibiotic drug sensitivity of imipenem resistant Pseudomonas aeruginosa （IRPA） in our hospital during 2012 to 2013, and provide the guidance for clinical rational use of antibiotics. Methods：All clinical specimens were collected, and then identified using VITEK2-Compact, analyzed drug sensitivity, Cefperazon-Sulbactam susceptibility testing was carried out using Kirby- Bauer method. Results：The 646 IRPA were isolated from 2012 to 2013, of which 20.1%-100% were resistant to cephalosporin antibiotics, 43.3% were resistant to ceftazidime, 20.1% were resistant to cefepime, 28.1%-30.4% were resistant to quinolone antibiotics, 8.0-12.9% were resistant to aminoglycoside, 24.5%-31.7% were resistant to β-1actamase inhibitor. Conclusion ： The condition of antimicrobial resistance of IRPA was quite severe, antibiotics should be selected according to clinical drug susceptibility results and suggested that the priority to choose cefepime and ceftazidime.